StockNews.AI
NUWE
StockNews.AI
119 days

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

1. Nuwellis plans Q1 2025 financial results release on May 13. 2. Conference call scheduled for business updates post financial results. 3. The Aquadex SmartFlow system aids patients with fluid overload. 4. NUWE is positioned in a growing medical tech market. 5. Investors can access the financial details via the Nuwellis website.

Earnings
-1.3%Current Return
VS
+1.59%S&P 500
$0.882504/22 04:22 PM EDTEvent Start
$0.87104/23 11:08 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may indicate growth potential. Companies with solid earnings reports often see stock price increases.

How important is it?

Increased transparency around business results can instill investor confidence. Quarterly results often reflect ongoing business health and future prospects.

Why Short Term?

The upcoming earnings report will influence investor sentiment quickly. Historical trends show immediate market reactions post-earnings calls.

Related Companies

MDTABTHOLX
April 22, 2025 16:05 ET  | Source: Nuwellis, Inc. MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X. About the Aquadex SmartFlow® System  The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. CONTACTS INVESTORS: Louisa SmithGilmartin Group LLC ir@nuwellis.com

Related News